ReShape Lifesciences Inc.
RSLS
$0.365
-$0.015-3.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -21.25% | 16.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.25% | 16.64% | |||
| Cost of Revenue | -43.02% | 2.65% | |||
| Gross Profit | -8.34% | 26.90% | |||
| SG&A Expenses | -48.59% | 0.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -39.62% | 0.85% | |||
| Operating Income | 63.54% | 14.26% | |||
| Income Before Tax | -11.49% | 0.32% | |||
| Income Tax Expenses | -16.67% | -60.00% | |||
| Earnings from Continuing Operations | -11.39% | 0.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.39% | 0.88% | |||
| EBIT | 63.54% | 14.26% | |||
| EBITDA | 63.72% | 14.26% | |||
| EPS Basic | 20.55% | 15.29% | |||
| Normalized Basic EPS | 22.11% | 33.00% | |||
| EPS Diluted | 20.55% | 15.29% | |||
| Normalized Diluted EPS | 22.11% | 33.00% | |||
| Average Basic Shares Outstanding | 40.18% | 17.02% | |||
| Average Diluted Shares Outstanding | 40.18% | 17.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||